Zentalis Pharmaceuticals, Inc. (ZNTL) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$35.2M

EPS$-1.42

Market Cap$195.8M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Julie Eastland

CEO & Executive Director

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Founded: 2014
Employees: 166
Headquarters

⚡

Core Efficiency

ROE?

-16.29%

ROA?

-12.19%

D/E Ratio?

0.34

📊

Profitability Ratios

Current Ratio?

6.93

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Aug 19, 2026 (in 132 days)

Annual Report (10-K) — Based on filing pattern

Aug 19, 2026

Predicted10-K

Mar 26, 2026

10-KQ4 20256d after period end

Nov 10, 2025

10-QQ3 20259d after period end

Aug 6, 2025

10-QQ2 20255d after period end

May 14, 2025

10-QQ1 20252d after period end

Mar 26, 2025

10-KQ4 20245d after period end

Nov 12, 2024

10-QQ3 202411d after period end

Aug 9, 2024

10-QQ2 20242d after period end

May 7, 2024

10-QQ1 20244d after period end

Loading company sections...

Zentalis Pharmaceuticals, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness